- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Treatment resistant depression
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 944KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 377KB)
Esketamine – July 2023
Esketamine: Nasal spray solution 28 mg in 0.2 mL; Spravato®
Last updated
27 October 2023